No abstract

No abstract

Objective The effect of alcohol consumption on the risk of coronary heart disease is controversial. Several studies have assessed the effects of alcohol on the formation of atherosclerotic plaques, but few studies have evaluated the chronic effects of alcohol consumption on the coronary artery diameter. We investigated whether alcohol consumption affects the coronary artery diameter. Methods This prospective study enrolled men who were undergoing coronary angiography at the First Affiliated Hospital of Chongqing Medical University from November 2016 to December 2017. The participants were categorized into three groups based on their drinking behavior: heavy drinking (>175 g/week in the last 2 years, n = 70), moderate drinking (>42 to ≤175 g/week in the last 2 years, n = 53), and nondrinking (lifetime alcohol consumption of <98 g, n = 79). The diameters of the left and right coronary arteries were compared among the three groups. Results No significant differences in the diameters of the left and right coronary arteries were observed among the three groups. Conclusions Alcohol consumption may not affect the diameter of the coronary arteries.

Background Current guidelines indicate we can consider a bridging strategy that uses intravenous, reversible glycoprotein inhibitors for patients that required surgery following recent stent implantation. However, no strong clinical evidence exists that demonstrates the efficacy and safety of this treatment. Therefore, in this study, the efficacy and safety of a bridging strategy that uses intravenous platelet glycoprotein receptor inhibitors will be evaluated. Methods A meta-analysis was performed on preoperative bridging studies in patients undergoing coronary stent surgery. The primary outcome was the success rate of no major adverse cardiovascular events (MACE). The secondary outcomes were the success rate of no reoperations to stop bleeding. Results A total of 10 studies that included 382 patients were used in this meta-analysis. For the primary endpoint, the success rate was 97.7% (95% CI 94.4–98.0%) for glycoprotein IIb/IIIa inhibitors, 98.8% (95% CI 96.0–100%) for tirofiban (6 studies) and 95.8% (95% CI 90.4–99.4%) for eptifibatide (4 studies). For secondary endpoints, the success rate was 98.0% (95% CI 94.8–99.9%) for glycoprotein IIb/IIIa inhibitors, 99.7% (95% CI 97.1–100%) for tirofiban (5 studies), and 95.3% (95% CI 88.5–99.4%) for eptifibatide (4 studies). Conclusion The results of this study showed that the use of intravenous platelet glycoprotein IIb/IIIa inhibitors as a bridging strategy might be safe and effective for patients undergoing coronary stent implantation that require surgery soon after.

No abstract